|
|---|
|
|
|
|
|
|
b****n
发帖数: 8 | 1 Address:
Email:
Cell phone:
Work phone:
Oct 28, 2013
Department of Homeland Security
USCIS Nebraska Service Center
P.O. Box 87103
Lincoln, NE 68501-7103
I-140 Immigration Visa Petition Under First Preference EB-1
Petitioner/Beneficiary: XX Z., Ph.D.
Category of Petition: Alien of Extraordinary Ability
Classification Sought: 203(b)(1)(A)
Nature of Submission: Original Submission
Dear Immigration Officer,
This letter is respectfully submitted in support of my petition for
classification as a qualified immigrant under the first preference as an
Alien of Extraordinary Ability. Specifically, the evidence submitted will
prove:
I. I am an alien of extraordinary ability on the basis of the following
facts:
1. I have authored scholarly articles in professional journals in my field.
2. I have made original scientific contributions of major significance to my
field.
3. I have been asked to judge the work of others.
II. I will continue to work in my area of extraordinary ability in the U.S.
III. My future stay will substantially benefit prospectively the U.S.
I. I am an alien of extraordinary ability on the basis of the following
facts:
I have many years of research experience in biology and biomedicine in very
prestigious institutions, which is summarized in the CV (Exhibit-Edu 1). In
2004, I began my PhD research in Chinese Academy of Sciences (CAS), the top
1 research institute in China and Asia according to Nature Publishing Index
2012 (Exhibit-Edu 2). I received my PhD degree from CAS in 2008 (Exhibit-Edu
3). Immediately after that, I joined Professor D.E.’s lab at University of
XX as a postdoc researcher. UXX has the only school of medicine in the U.S.
that ranks in the top 4 in both research and primary care education
according to US News 2013 (Exhibit-Edu 4). After 5 years’ postdoc research
at UXX, I am now appointed by UXX as an Assistant Professional Research
Biologist (See Employment Verification). With these research experiences, I
have made significant contributions and established my extraordinary ability
in my field.
My contributions have dramatically advanced molecular medicine and genomic
biology, and resulted in 20 scientific papers (Exhibit-Pub 1-20) in
professional journals. On many of these papers, I am the first author or the
key person. These research papers have been cited 562 times (Exhibit-Pub 32
) by researchers around the world, evidencing the worldwide impact. Owing to
my expertise, I have been invited to judge the work of others 18 times (
Exhibit-Rev 1-18) for leading journals and have been considered as one of
the best reviewers (Exhibit-RL 5). Through these publications and original
contributions, I have achieved sustained national and international acclaim
and reputation in my field on a much higher scale than the vast majority of
others in my research area. Consistent with these facts, leading experts in
my field have provided 5 independent advisory evaluations (1 from Ireland, 1
from Germany, 2 from USA, and 1 from Korea, Exhibit-RL 1-5) that have
explained, in detail, how my contributions were “original” and how they
were of “major” significance. The following sections will discuss the
above evidence in further detail.
1. My Authorship of Scholarly Articles in professional Journals in My Field
I have published 20 scientific articles in professional journals with
worldwide circulation. The full copies of my publications are packed as
Exhibit-Pub 1-20. The brief summary for the journals where I have published
my articles is shown in Table 1.
Table 1. The summary for the journals that have published my articles
Journal Name IF (2012) IF (5-year) # of My Papers
J Molecular Medicine 4.768 5.012 1
J Biomed Mater Res (A) 2.834 3.103 4
Biomaterials 7.604 8.496 3
PLoS one 3.730 4.244 1
Stem Cells 7.701 8.368 1
Tissue Engineering 4.065 4.623 3
Neuroscience Letters 2.026 2.146 3
Growth Factors 2.195 2.337 1
Proc Am Thor Soc New journal, IF not available now 1
Acta Hydrobiologica Sinica In Chinese, with English abstract 1
Wuhan University J Nat Sci In Chinese, with English abstract 1
TOTAL 20
Impact Factor (IF), which is published by Thomson Reuters on the basis of
the citation rates of papers, is widely used to evaluate the impact of
journals. Generally, the higher IF score means higher impact. In addition,
the reputation is also a criterion for evaluating a journal. Here I am
briefly describing the reputation and IFs for these journals:
o Journal of Molecular Medicine (JMM) publishes reports describing major
advances in the understanding, prevention, diagnosis, and treatment of human
disease through the application of molecular biology and gene technology.
JMM is the continuation of the Berliner Klinische Wochenschrift (1864), one
of the oldest and most prestigious European journals in which great
scientists such as Paul Ehrlich (Nobel prize, 1908), Robert Koch (Nobel
prize, 1905) and Otto Warburg (Nobel prize, 1931) published their seminal,
epoch-making discoveries. JMM’s IF is ranked # 18 /121 in medicine,
research & experimental (Exhibit-Pub 21).
o Journal of Biomedical Materials Research Part A is the official journal
of the Society For Biomaterials (USA), the Japanese Society for
Biomaterials, the Australasian Society for Biomaterials, and the Korean
Society for Biomaterials, ranked #8 among all journals in materials science
& biomaterials (Exhibit-Pub 22).
o Biomaterials is an international journal covering the science and
clinical application of biomaterials. It publishes original papers and
authoritative review and opinion papers dealing with the most important
issues facing the use of biomaterials in clinical practice. Biomaterials is
ranked #1 among all journals in materials science & biomaterials (Exhibit-
Pub 23).
o PLoS One is a peer-reviewed journal dedicated to publishing high
quality research. Submissions are considered on the basis of scientific
validity and technical quality (Exhibit-Pub 24).
o Stem Cells covers all aspects of stem cells embryonic stem cells/
induced pluripotent stem cells; tissue-specific stem cells; stem cell
technology: epigenetics, genomics, proteomics, and metabonomics; cancer stem
cells; translational and clinical research; and regenerative medicine. Stem
cells is ranked #2 among all journals in cell & tissue engineering (Exhibit
-Pub 25).
o Tissue Engineering is the preeminent, biomedical journal advancing the
field with cutting-edge research and applications on all aspects of tissue
growth and regeneration, ranked # 8 among all journals in cell & tissue
engineering (Exhibit-Pub 26).
o Neuroscience Letters is devoted to the rapid publication of short, high
-quality papers. Only papers that will make a significant addition to the
literature in the field will be published (Exhibit-Pub 27).
o Growth Factors is an international and interdisciplinary vehicle
publishing new knowledge and findings on the regulators of cell
proliferation, differentiation and survival (Exhibit-Pub 28).
o Proc Am Thor Soc is an official international journal of the American
Thoracic Society, the Annals of the American Thoracic Society (Annals ATS),
formerly the Proceedings of the American Thoracic Society (PATS). It
delivers up-to-date and authoritative coverage of adult and pediatric
pulmonary and respiratory sleep medicine and adult medical critical care.
The scope of the journal encompasses content that is applicable to clinical
practice, and the clinical advancement of public health (Exhibit-Pub 29).
o Acta Hydrobiologica Sinica (AHS) is launched in 1955 and sponsored by
the Institute of Hydrobiology, Chinese Academy of Sciences, and the Chinese
Society for Oceanology and Limnology. AHS is a comprehensive academic
journal dedicated to the timely publication of original research ideas and
results in all fields of hydrobiology (Exhibit-Pub 30).
o Wuhan University Journal of Natural Sciences aims to promote rapid
communication and exchange between the world and Wuhan University, as well
as other Chinese universities and academic institutions. It mainly reflects
the latest advances being made in many disciplines of scientific research in
Chinese universities and academic institutions (Exhibit-Pub 31).
Besides the journal impact factor and reputation, the quality of a paper can
be reflected by the citations in other people’s work. Several tools with
different strengths are available for the evaluation of citations. For
example, Google Scholar Citations has the most powerful search engine so
that it can find the biggest number of citations; however, it is easier to
show the citation distribution in countries through Web of Knowledge (
Thomson Reuters). So I will next use these tools, depending on different
purposes, to show you the citations of my papers.
Figure 1 shows the total citations (left) and annual citations (right) of my
papers according to Google Scholar Citations. It shows that my papers have
been cited over 560 times in total and the annual citations are rising (More
information can be found in Exhibit-Pub 32), indicating that my papers have
been widely recognized.
Figure 1. The total and annual citations of my papers *
(* The total citation from another tool Scopus is attached immediately after
Exhibit-Pub 32, with the exhibit name SNEP-32)
To be emphasized, the average citation rate of my papers is >28 (562/20),
which is significantly higher than the average citation rates in clinical
medicine (12.84) and materials science (7.76) (Exhibit-Pub 35), indicating
that my publication is superior to my peers.
Owing to the novelty and importance of my work, the authors from many
countries have cited my papers. The Web of Knowledge displayed the countries
where the researcher have cited my papers, which include China, USA, Korea,
Germany, Italy, Japan, England, Switzerland (see the top 20 in Figure 2,
detailed in Exhibit-Pub 33), suggesting that my papers have been
internationally recognized.
Figure 2. Top 20 countries where researchers have cited my papers
Furthermore, my papers have been cited by many of very prestigious journals.
The analysis with Google Scholar Citations shows you all the articles and
journals that have cited my papers (Exhibit-Pub 32), while Table 2 shows you
, in detail, 10 examples of prestigious journals that have cited my papers.
Details about the 10 citing papers, the relevant journal names and their
impact factors are shown in Exhibit-Pub 34. They are also positioned in
Exhibit-Pub 32 with red flags.
Table 2. 10 examples of prestigious journals citing my papers
Journal name IF 2012 IF 5-year
Nature Reviews Genetics 41.063 36.4
Nature Immunology 26.199 25.005
Nature Reviews Neuroscience 31.673 35.888
Biomaterials 7.604 8.496
Molecular and Cellular Biology 5.372 5.745
Stem Cells 7.701 8.368
Biotechnology Advances 9.599 11.85
Cell Research 10.526 10.216
Molecular Therapy 7.041 6.457
P.N.A.S 9.737 10.583
In summary, I have published 20 scientific papers in professional journals.
Some journals are # 1 in the field and some are very top and prestigious
journals. These papers have been cited 562 times by other researchers over
20 countries, demonstrating the worldwide impact. The average citation of my
papers is much higher than the average citation rate in the field.
Therefore, my publication record is extraordinary and my works constitute
authorship of scholarly articles in professional journals that have
significantly influenced my field.
2. My Original Scientific Contributions of Major Significance to My field
Although the significance of my scientific contributions can be generally
reflected by 20 articles that have been cited over 20 countries for 562
times, more details about my work will further clarify that. Specifically, I
have made multiple, original, recognized contributions to the field of
molecular medicine and molecular biology. The aim of molecular medicine is
to treat diseases by developing of molecular approaches such as gene
engineering and recombinant proteins. These approaches, combined with cells,
biomaterials, and engineering, can be further applied to tissue engineering
for repairing or replacing damaged tissues such as blood vessels, bone,
cartilage, skin, muscle etc. Molecular medicine is at the forefront of
modern medicine and is becoming increasingly important, because many
problems with patients cannot be solved with traditional treatments. For
example cardiovascular diseases (CVDs) are the number one cause of death
globally: An estimated 17.3 million people died from CVDs in 2008,
representing 30% of all global deaths. The number will increase to reach 23.
3 million by 2030 (World Health Organization’s report: http://www.who.int/mediacentre/factsheets/fs317/en/). An essential step to cure of CVDs is to regenerate blood vessels or promote neovascularization. However, it is very challenging to regenerate blood vessels in many of damaged tissues or organs. Although some treatments are available clinically, they mostly are of low efficacy or they rely on autografts or allografts but have associated risks, with autografts needing an additional surgical site and limits to supply, and allografts having potential risks of disease transmission and long-term complications. To solve these challenging obstacles, I have made significant contributions to regeneration of blood vessels and therapeutic neovascularization by development of molecular medicine approaches, which include the recombination of fibrin-affinity fusion growth factor, invention of 3-D biomaterial scaffolds, reconstruction of targeted repair system based on fibrin and collagen. These cutting-edge technologies have been proved to be very efficacious in neovascularization and improvement of wound healing. My contributions in this area have shown considerable value in clinical applications and brought great hope for millions of patients with CVDs (Exhibit-RL 1-5).
In one of my work, I developed a novel molecular technology for targeted
improvement of neovascularization. It has been proved that bFGF can set the
stage for neovascularization during embryonic development. Therefore, bFGF
is supposed to be a reagent for therapeutic neovascularization. However,
previous work with the local application of bFGF to wound sites resulted in
subtle effects, because bFGF diffused rapidly via conventional
administration ways, thus markedly lowered its effects. To solve this
clinical obstacle, I developed a molecular technology for targeted
application of bFGF. Targeted therapy is a new generation of therapeutics,
by which the drug acts only on specific targets and avoids adverse effects
on other tissues. First, a fibrin binding peptide Kringle 1 (K1) was fused
to bFGF, which successfully endowed bFGF with fibrin binding ability. Second
, the recombinant K1bFGF was incorporated with fibrin. In vitro assay with
fibrin showed that K1bFGF was released in a sustained and controlled manner,
rather than the burst release with natural bFGF. After application to the
wound sites in animals, fibrin/K1bFGF markedly induced vascular endothelia
cells proliferation and new blood vessel formation at wound sites. Six weeks
after treatment, the wound sites treated with fibrin/K1bFGF were repaired
completely, but the control samples did not lead to significant repair.
These results demonstrated a very promising technology that could be used
for clinical therapy of CVDs and wound healing. The further application of
this technology in tissue engineering will be of great value.
This work has been published in Journal of Molecular Medicine with my name
as the first author (Exhibit-Pub 1) and highly acclaimed by independent
experts: “The complex of fibrin with K1゜FGF strikingly regenerated the
blood vessel network and improved wound repair, demonstrating a powerful
tissue〆ngineered product.” (Prof. BB, Exhibit-RL 1); “Dr. XX Z. was the
first person that creatively developed the Fibrin/K1-bFGF system and
successfully established an efficacious method for targeted improvement of
neovascularization. This work showed a very promising perspective for the
therapy of ischemic diseases clinically.” (Prof. AA, Exhibit-RL 2). This
work is also highlighted in experts’ review papers. For example, in Prof.
BB’s (an independent advisory expert) paper, it says “A recent approach to
tether growth factors has been investigated by Z. et al. Kringle domains
present on the enzymogen plasminogen have high affinity for fibrin...
Analysis of binding showed that K1bFGF bound fibrin with a greater affinity
than bFGF alone, and was also retained for longer in a fibrin scaffold than
bFGF… results showed that fibrin containing K1bFGF significantly enhanced
neovascularization… it was shown that fibrin scaffolds containing K1bFGF
had significantly more proliferating cells than control groups, highlighting
the importance of prolonging the diffusion of growth factors in vivo.” (
Tissue Engineering: Part B, 2009, Ref. 117, Exhibit-Con1).
Moreover, this work attracted editor’s special attention. Dr. AA, an editor
of the Journal of molecular medicine, “thought that this paper was the
best paper in that issue, so he wrote a three-page commentary on this work”
in that issue (Exhibit-RL 2): “In this issue, Z. et al. demonstrate
improved neovascularization and wound repair by targeting human bFGF to
fibrin… This system successfully induced neovascularization by delivering
K1-bFGF in a sustained fashion. The result was a microenvironment that
promoted cell growth, angiogenesis, and tissue regeneration… This strategy
could potentially be used in other clinical settings because plasminogen and
angiostatin can promote blood vessel formation in ischemic cardiovascular
disease and turn the process off in cancer, respectively. Z. et al. have
picked the targets and vehicles to potentially do both”(detailed in Exhibit
-Con2). Therefore, this work demonstrates a significant contribution to
therapeutic neovascularization.
Scaffolds with 3-D structure can mimic the in vivo environment and promote
tissue regeneration. To achieve this goal, I developed a 3-D scaffold based
on fibrin protein for blood vessel regeneration. Scanning electron
microscopy revealed that the microscopic structure of the 3-D scaffold was
honeycomb-like, with an average pore size of 50 µm, demonstrating a
similar 3-D structure to that of natural fibrin clots. Therefore, the
polyporous 3-D structure is suitable for cell migration and growth. Further,
fibrin fibers were cross-linked and well organized, and provided potential
binding sites for signal molecules participating in tissue regeneration. To
target bFGF to the 3-D fibrin scaffold, I fused Kringle 4 (K4) peptide to
bFGF and resulted in a fusion molecule K4bFGF. Kringle 4 is a shortened
analog to Kringle 1 but has a lower molecular weight, thus increased yield
when expressed in bacteria. In vitro assays showed that 3-D fibrin scaffold
could bind specifically to K4bFGF and deliver K4bFGF in a site-specific
manner. Cell culture assay showed the 3-D fibrin scaffold significantly
promoted cell migration and proliferation. Subcutaneous implantation of 3-D
fibrin scaffolds bound with K4bFGF, but not with natural bFGF, induced
significant formation of new blood vessels in animals. Moreover, the
regenerative tissues were integrated well with the fibrin scaffolds,
suggesting its excellent biocompatibility and therapeutic prospect.
This work has been published in Tissue Engineering (Part A) with my name as
the first author (Exhibit-Pub 2) and demonstrated a significant advancement
in regeneration of blood vessels. Due to its great value in clinical
application, this work has been highlighted in Dr. Koutsopoulos’ (
Massachusetts Institute of Technology, Exhibit-Con 3) review paper: “Z. et
al. studied the release of growth factors through a modified fibrin
nanofiber hydrogel in which basic fibroblast growth factor (bFGF) was
tethered to fibrin nanofibers via the kringle domains that are present on
plasminogen. In vivo studies showed that fusion of the Kringle domain (K4)
to the N-terminus of bFGF and binding to the fibrin nanofibers resulted in
longer retention and prolonged release of the tethered bFGF compared to the
native bFGF encapsulated in the fibrin hydrogel” (Advanced Drug Delivery
Reviews, IF 12.888, 2012, Ref 75, Exhibit-Con 3/4). Moreover, this work has
been highly acclaimed by independent experts: “The modified fibrin scaffold
obtained great mechanical strength after vacuum lyophilization…Millions of
people in the world need therapeutic neovascularization due to pathological
ischemia or accidental injures. This impressive work showed a very
promising avenue to the therapeutic neovascularization in patients, and
represents a significant contribution to regenerative medicine.” (Prof. DD,
Exhibit-RL 4); “More expressively, he next developed a 3-D fibrin scaffold
to enable cells grow in 3-D environment rather than in 2-D space, which
allowed cells to interact with each other. By incorporating the hybrid K4-
bFGF into the 3-D fibrin scaffold, his results showed that the repair system
markedly improved new blood vessel growth and wound healing. His work has
greatly advanced the therapeutic regeneration of blood vessels.” (Prof. EE,
Exhibit-RL 5).
In the next work, I developed another type of targeted-therapy technology on
the basis of collagen for neovascularization. Collagen is a type of
biomaterial that is widely used in tissue engineering but the natural
collagen molecules cannot be incorporated with bFGF. I recombined bFGF into
a fusion protein by introduction of collagen binding domains (CBDs) via gene
engineering technology. The resulting CBD-bFGF could bind specifically to
collagen that has been fabricated into a 3-D scaffold. By incorporation of
CBD-bFGF to collagen scaffold, the diffusion problem with bFGF was
successfully solved. Moreover, the collagen scaffold could provide 3-D space
supporting cell migration and growth. Upon implantation, this system
markedly promoted neovascularization and endothelial cell growth.
This work has been published in Journal of Biomedical Materials Research (
Part A) with my name as the first author (Exhibit-Pub 3) and shown a
significant improvement of neovascularization via use of molecular medicine
approach. This work was highlighted in Dr. CHONG-SU CHO’s review article (
Seoul National University, ranked #1 in Korea, Exhibit-Con5): “Z. et al
introduced two CBDs into the human bFGF to develop a collagen based wound
targeting repair system. The results showed that the bFGF with the CBD
derived from collagenase (C-bFGF) promoted vascularization at the implanted
sites more effectively than bFGF…”(Annals of Biomedical Engineering, 2010,
Ref. 87, Exhibit-Con6). Due to my successful application of CBDs in
collagen-based targeted technology, Dr. Eiry Kobatake’s group (Tokyo
Institute of Technology, ranked #4 in Japan, Exhibit-Con 7) used this work
as a basis to design the new multi-functional extracellular matrix proteins
that promote tube formation of endothelial cells. Please see the details on
page 2978 of Exhibit-Con 8: “Here, we focused on the collagen-binding
domain (CBD)…[28-30]. Thus, we constructed new fusion proteins in order to
obtain the multiple activities” (Biomaterials, 2008, Ref. 29, Exhibit-Con 8
). Moreover, this work are highly recognized by independent experts and
shown the potential for the application in tissue engineering: “this
product strikingly promoted vascular endothelial cell growth and wound
healing in rat preclinical studies. This work demonstrated an innovative
tissue engineering product that could be clinically translated.” (Prof. BB,
Exhibit-RL 1); “he successfully developed the collagen/ growth-factor
system… for the purpose of therapy of ischemia… These extensive
contributions significantly promoted the research in biomedicine.”(Prof. AA
, Exhibit-RL 2). Therefore, my work has been recognized to be significant to
the field. These contributions to the therapeutic neovascularization with
targeted technologies could potentially benefit millions of patients who are
suffering from ischemic diseases including CVDs.
The facts above just show some representatives of my contributions to the
field of molecular medicine; all of my other contributions to molecular
medicine and related fields are reflected by the full list of papers. My
most recent work is focused on genome biology, which is one of the hottest
areas in molecular biology. Genomics is changing the way people think about
life sciences, and it will benefit the entire medicine including molecular
medicine and genomic medicine. A fundamental step towards the genomic
medicine is to decode the genetic information within 3 billion of human DNA
bases. However, most of the DNA sequences are not functionally annotated due
to the lack of high throughput technologies. I have therefore developed a
massively parallel technology (named fast-UTR) to systematically unveil the
regulatory functions of 3’ untranslated region (3’UTR) sequences. 3’UTR
is a partial sequence of mRNA and plays critical roles in controlling of
gene expression. The human genome contains thousands of 3’UTR sequences,
but only very few of them have been investigated with low throughput methods
. By using fast-UTR, I, as a “key role” (See Employment Verification),
have revealed the regulatory effects of 450kb conserved 3’UTR sequences on
mRNA abundance, mRNA decay rate and translation. I further systematically
identified the functional cis-elements within these sequences. This exciting
work for the first time demonstrated a powerful technology that can be used
to functionally unveil DNA or RNA sequences in genome wide.
One paper about this work has been published in Proc Am Thor Soc with my
name as the first author (Exhibit-Pub 5), which is the only paper so far
that has been published for systematic understanding of 3’ untranslated
regions (Exhibit-Con9), demonstrating a pioneering work in this area. More
excitingly, a recent manuscript about this project has been submitted to
Nature Biotechnology (IF 32.438) with my name as the first author and is now
under review (Exhibit-Con 10). Another manuscript is ready to submit (
Exhibit-Con 11). These facts demonstrate that I am continuously making
significant contributions. Due to the novelty and importance, this work is
highly praised by experts. Prof. N. CC, an expert in genome biology in Yale
University, gives an independent evaluation: “The fast-UTR is a highly
integrative tool encompassing aspects of molecular biology, cellular biology
, genome biology, and computational biology… This clever system has been
shown to be very efficient in systematic quantification of the regulatory
effects of 3’UTRs on proteins. The results also elucidated the
relationship between the mRNA level and protein level controlled by 3’UTRs.
Undoubtedly, this original work is a significant innovation in this field…
This technology and the findings could be potentially useful in genomic
medicine in future” (Exhibit-RL 3). “The discoveries in this work have
deepened the understanding of the functions of evolutionarily conserved 3’
UTRs; this novel technology will dramatically advance the genome research”,
independently evaluated by Prof. DD (Exhibit-RL 4). Therefore, these recent
accomplishments and ongoing progress prove my sustained extraordinary
ability to do high quality of research.
In Summary, my work has been shown with great values in both clinical
application and basic research; my work has been widely cited in the world
by many of prestigious scientific journals and famous institutions; my work
has been totally cited for 562 times over 20 countries as supporting data or
used a the basis in other research. The comparison of my publication and
citations to the average of faculty scholarly productivity in TOP research
universities indicates my superiority to peers. Table 3 shows the average
publication and citations in top 10 universities in biological and
biomedical sciences, which clearly shows that my “publication”, total “
citations” and “citations per paper” are all much higher than the average
level with the faculty in top universities, indicating that I am far
superior to my peers.
Table 3. Comparison of my publication and citations to the average levels
with the faculty in TOP 10 universities (The full table is shown in Exhibit-
Con 12)
Institution Publications per faculty Citations per faculty
Citations per paper
1 U. of California at San Diego 16 327 16
2 Gerstner Sloan-Kettering Graduate School of Biomedical Sciences 14
324 18
3 U. of California at San Francisco 10 234 17
4 Vanderbilt U. 10 138 11
5 U. of North Carolina at Chapel Hill 9 161 14
6 U. of Massachusetts Medical School 8 169 17
7 Mount Sinai School of Medicine 10 128 10
8 U. of Colorado at Denver and Health Sciences Center 7 110 12
9 U. of Cincinnati 10 137 10
10 New York U. 8 134 13
Average 10 186 14
My Publication and Citations 20 > 560 > 28
Moreover, my work has been highly acclaimed by five independent advisory
experts (1 from Ireland, 1 from Germany, 2 from USA, and 1 from Korea,
Exhibit-RL 1-5), and they have testified the “originality” and “major
significance” of my contributions. All these facts therefore prove that I
have made multiple original contributions of major significance to my field.
3. My Service As a Judge of the Work of Others
Owing to my outstanding expertise and excellent reputation in my field, I
have been invited to judge the work of others for 18 times by professional
journals, which are shown in the list below. Notably, all these invitations
were made under my name (Exhibit-Rev 1-18).
o Journal of Materials Chemistry B
o Soft Matter
o Biomaterials Science
o International Journal of Nanomedicine
o Medical & Biological Engineering & Computing
o Australasian Physical & Engineering Sciences in Medicine
o Science China-Chemistry
All of these journals are professional publications (Exhibit-Rev 19-25). For
example, Journal of Materials Chemistry B (JMC-B), a very prestigious
journal, is an official publication of Royal Society of Chemistry and has an
impact factor 6.10. The journal is interdisciplinary, publishing work of
international significance on all aspects of materials chemistry related to
biology and medicine. It publishes original research that demonstrates
novelty and advance (Exhibit-Rev 19). Softer Matter has an impact factor 3.
909 and is ranked #8/83 (Exhibit-Rev 20); Biomaterials Science, opened in
2012, is an international, high impact journal (Exhibit-Rev 21).
International Journal of Nanomedicine (IJN), endorsed by the American
Society for Nanomedicine, is an international, peer-reviewed journal, with
an impact factor 3.463 (Exhibit-Rev 22).
“To ensure the quality of outgoing articles, we only recruit researchers
with outstanding credentials as manuscript reviewers. Dr. Z.’s good
reputation makes him an ideal reviewer for IJN… Dr. Z.’s research
expertise and credentials match our high criteria and I consider him as one
of the best reviewers.” (Prof. EE, an editor of IJN, Exhibit-RL 5 and
Exhibit-Rev 22). Owing to my outstanding expertise and good reputation, I
was “recognized as an expert in the field” (Exhibit-Rev 1, 2, 3) and was
invited to review the manuscripts for these professional journals. To screen
papers of high quality, I always seriously evaluate the work of others for
novelty, accuracy, and importance to the field. My service as a reviewer not
only contributes to my field, but also demonstrates my extraordinary
expertise and international acclaim.
The Summary for the Significance of the Evidences:
• I have been doing research in very prestigious institutions
including Chinese Academy of Sciences and University of XX; I am now
appointed as an Assistant Professional Research Biologist at UXX and
continuously doing high quality of research.
• I have published 20 peer-reviewed scientific papers; the papers
have been cited over 560 times by the researchers from over 20 countries.
• I have made original scientific contributions of major
significance to my field. I have been widely recognized by international
experts and have sustained national or international acclaim: “Dr. XX Z.’s
creative work undoubtedly demonstrated his extraordinary ability in
research” (Prof. AA, Exhibit-RL 2); “Dr. XX Z. has made outstanding
accomplishments… Based on his impressive publication record and reputation,
I consider him as one of the top scientists in the field.” (Prof. DD,
Exhibit-RL 4); “Dr. Z. has authored many peer-reviewed papers, which have
been cited over 500 times, demonstrating that he has been internationally
recognized and shown himself to be of extraordinary ability” (Prof. CC,
Exhibit-RL 3).
• I have independently judged the work of others for 18 times for
the professional scientific journals. I have been considered as an ideal and
one of the best reviewers.
• The totality of these evidences demonstrates that I am one of
that small percentage who have risen to the very top of the field of
endeavor, and that I have sustained national or international acclaim and
that my achievements have been recognized in the field of expertise.
Therefore, I am an alien of extraordinary ability.
II. I will continue to work in my area of extraordinary ability in the U.S.
I am very interested in biology and biomedicine; I have demonstrated my
extraordinary ability in these aspects. “Owing to his outstanding
accomplishments and expertise, he has been employed here as an Assistant
Professional Research Biologist since July 28, 2013. He will continue to
play a key role in our studies of the roles of 3’UTRs in
posttranscriptional gene regulation using the fast-UTR system and other
relevant tools and in our studies of micro-RNAs in airway epithelial cells”
(See Employment Verification). Specifically, I will systemically
investigate the post-transcriptional effects of human 3’UTR sequences on
gene expression and identify the functional cis-elements contained in active
3’UTRs in the human genome. Then I will screen the trans-acting factors in
airway epithelial cells that interact with these cis-elements and elucidate
their roles in gene expression. With these systematic studies, I expect to
discover novel regulatory cis-elements and relevant trans-acting factors
including miRNAs and binding proteins. Therefore, I will definitely continue
to work in my area of extraordinary ability in the United States.
III. My future stay will substantially benefit prospectively the U.S.
My future work will lead to understanding of the functions of 3’UTR
sequences and microRNAs in human genome. The research in genome biology will
extensively benefit the whole country and the world. For example, between
1988 and 2010, human genome sequencing projects and associated research and
industry activity, directly and indirectly, generated economic activity
totaling $796 billion, personal income exceeding $244 billion, and 3.8
million job-years of employment. The government’s initial investment
yielded an economic return of 141 to 1. In 2010 alone, genomics-related
economic activity yielded over $3.7 billion in federal taxes and $2.3
billion in state and local taxes. (More information can be found in NIH
official report: http://officeofbudget.od.nih.gov/pdfs/FY13/FY2013_Overview.pdf). More importantly, the findings in genomic studies could be applied in genomic medicine. Genomic medicine is the next generation of medicine that can be used in the therapy of cancer, HIV infection, and heart disease etc., so it will remarkably benefit public health in the U.S.. Owing to my demonstrated extraordinary ability, my future stay will substantially benefit prospectively the United States. “Therefore, it is definitely in the U.S. national interest for Dr. Z. to remain in the U.S. and to continue his research”(Prof. CC, Exhibit-RL 3); “His continued presence in the United States will certainly be highly beneficial to the United States”(Prof. BB, Exhibit-RL 1).
I sincerely hope that I have provided you with the information and
documentation necessary and sufficient to approve my I-140 petition. I
deeply appreciate your kind consideration and care of this application!
Respectfully yours,
XX Z., PhD
Assistant Professional Research Biologist
Department of Medicine
University of XX
INDEX OF EXHIBITS
Education and Research:
Exhibit-Edu 1 My Curriculum Vitae
Exhibit-Edu 2 Ranking of Chinese Academy of Sciences
Exhibit-Edu 3 Copy of My PhD Certificate and Equivalency Evaluation
Exhibit-Edu 4 Ranking of University of XX
Employment Verification:
Verification of Employment for My Postdoc Research and Current Employment
Publication:
Exhibit-Pub 1-20 20 of My Peer-reviewed Publications
Exhibit-Pub 21-31 Description, Impact Factor and Ranking of 11 Journals
in
which I have published papers
Exhibit-Pub 32 Paper Citation Report based on Google Scholar and
Scopus
Exhibit-Pub 33 Paper Citation Report based on Web of Knowledge
Exhibit-Pub 34 10 Examples of Papers Citing My Work
Exhibit-Pub 35 Average Citation Rates for Paper by Field (2002-
2012)
Recommendation Letters From Five Independent Experts:
Exhibit-RL 1 Professor A. BB’s Letter (Ireland)
Exhibit-RL 2 Professor F. AA’s Letter (Germany)
Exhibit-RL 3 Professor N. CC’s Letter (USA)
Exhibit-RL 4 Professor L. DD’s Letter (USA)
Exhibit-RL 5 Professor D. EE’s Letter (Korea)
Contributions:
Exhibit-Con 1 Dr A. BB’s Paper Citing My Work
Exhibit-Con 2 Dr F. AA’s Editorial Commentary on My Work
Exhibit-Con 3 Dr. Koutsopoulos’ Paper Citing My Work
Exhibit-Con 4 Impact Factor and Ranking of Advanced Drug Delivery
Reviews
Exhibit-Con 5 Ranking of Seoul National University
Exhibit-Con 6 Dr CHONG-SU CHO’s paper Citing My Work
Exhibit-Con 7 Ranking of Tokyo Institute of Technology
Exhibit-Con 8 Dr Eiry Kobatake’s Paper Citing My Work
Exhibit-Con 9 Search Results for Work related to My Current Research in
Google
Exhibit-Con 10 My Manuscript Submitted to Nature Biotechnology
Exhibit-Con 11 My Ready-to-submit Manuscript
Exhibit-Con 12 Top Research Universities Faculty Scholarly Productivity
Index
Reviewing the Work of Others:
Exhibit-Rev 1-18 Evidence for My Reviewing of the Work of Others
Exhibit-Rev 19-25 Scientific Journals Relevant to My Reviewing Work | N*******d
发帖数: 1316 | | a******t
发帖数: 319 | | s*s
发帖数: 535 | | y********l
发帖数: 794 | | s********s
发帖数: 3945 | 6 恭喜恭喜！多谢分享。
【在 b****n 的大作中提到】
: Address:
: Email:
: Cell phone:
: Work phone:
: Oct 28, 2013
: Department of Homeland Security
: USCIS Nebraska Service Center
: P.O. Box 87103
: Lincoln, NE 68501-7103
: I-140 Immigration Visa Petition Under First Preference EB-1
| l*******7
发帖数: 627 | 7 cong~
【在 b****n 的大作中提到】
: Address:
: Email:
: Cell phone:
: Work phone:
: Oct 28, 2013
: Department of Homeland Security
: USCIS Nebraska Service Center
: P.O. Box 87103
: Lincoln, NE 68501-7103
: I-140 Immigration Visa Petition Under First Preference EB-1
| h*******n
发帖数: 1328 | 8 恭喜恭喜
【在 b****n 的大作中提到】
: Address:
: Email:
: Cell phone:
: Work phone:
: Oct 28, 2013
: Department of Homeland Security
: USCIS Nebraska Service Center
: P.O. Box 87103
: Lincoln, NE 68501-7103
: I-140 Immigration Visa Petition Under First Preference EB-1
| G**S
发帖数: 1108 | | s***s
发帖数: 2360 | | | | b*l
发帖数: 1118 | | R*******d
发帖数: 13640 | | W*******n
发帖数: 2762 | | w****n
发帖数: 175 | 14 zang~~
【在 b****n 的大作中提到】
: Address:
: Email:
: Cell phone:
: Work phone:
: Oct 28, 2013
: Department of Homeland Security
: USCIS Nebraska Service Center
: P.O. Box 87103
: Lincoln, NE 68501-7103
: I-140 Immigration Visa Petition Under First Preference EB-1
| c*******a
发帖数: 1541 | 15 Marked
★ 发自iPhone App: ChineseWeb 8.1
【在 b****n 的大作中提到】
: Address:
: Email:
: Cell phone:
: Work phone:
: Oct 28, 2013
: Department of Homeland Security
: USCIS Nebraska Service Center
: P.O. Box 87103
: Lincoln, NE 68501-7103
: I-140 Immigration Visa Petition Under First Preference EB-1
| s******t
发帖数: 913 | 16 Big big big cong!
【在 b****n 的大作中提到】
: Address:
: Email:
: Cell phone:
: Work phone:
: Oct 28, 2013
: Department of Homeland Security
: USCIS Nebraska Service Center
: P.O. Box 87103
: Lincoln, NE 68501-7103
: I-140 Immigration Visa Petition Under First Preference EB-1
| s*********x
发帖数: 1923 | | v*****e
发帖数: 309 | | H******6
发帖数: 77 | | u****r
发帖数: 2053 | | | | d***y
发帖数: 8107 | | h*****a
发帖数: 389 | | w****2
发帖数: 5760 | | D******K
发帖数: 557 | | b*********f
发帖数: 2125 | 25 10yuede ...恭喜了！
沾点喜气！！！ | C********1
发帖数: 160 | 26 Thanks so much for sharing!
【在 b****n 的大作中提到】
: Address:
: Email:
: Cell phone:
: Work phone:
: Oct 28, 2013
: Department of Homeland Security
: USCIS Nebraska Service Center
: P.O. Box 87103
: Lincoln, NE 68501-7103
: I-140 Immigration Visa Petition Under First Preference EB-1
| h*******e
发帖数: 142 | | s*******c
发帖数: 1366 | | k*f
发帖数: 58 | | p****a
发帖数: 631 | 30 好人，沾喜
【在 b****n 的大作中提到】
: Address:
: Email:
: Cell phone:
: Work phone:
: Oct 28, 2013
: Department of Homeland Security
: USCIS Nebraska Service Center
: P.O. Box 87103
: Lincoln, NE 68501-7103
: I-140 Immigration Visa Petition Under First Preference EB-1
| | | A******d
发帖数: 571 | 31 牛！恭喜～！
assistant professional research biologist是个什么title,从来没听说过？
你是从哪里找的faculty average citation/publication的？
【在 b****n 的大作中提到】
: Address:
: Email:
: Cell phone:
: Work phone:
: Oct 28, 2013
: Department of Homeland Security
: USCIS Nebraska Service Center
: P.O. Box 87103
: Lincoln, NE 68501-7103
: I-140 Immigration Visa Petition Under First Preference EB-1
| l***d
发帖数: 846 | | A******d
发帖数: 571 | 33 再问个问题，那个Faculty Scholarly Productivity Index是指2007年一年的数据吧，
那你的20篇文章是多年积累起来的吧？这样能比吗？
还有我觉得我特别苦逼，我这个领域冷门的都找不到，最多只能算在biology里面，然
后biology的平均引用都很高的，衬托的我的引用更加低。这种该怎么办？
【在 b****n 的大作中提到】
: Address:
: Email:
: Cell phone:
: Work phone:
: Oct 28, 2013
: Department of Homeland Security
: USCIS Nebraska Service Center
: P.O. Box 87103
: Lincoln, NE 68501-7103
: I-140 Immigration Visa Petition Under First Preference EB-1
| c**********n
发帖数: 1982 | 34 gxgx
【在 b****n 的大作中提到】
: Address:
: Email:
: Cell phone:
: Work phone:
: Oct 28, 2013
: Department of Homeland Security
: USCIS Nebraska Service Center
: P.O. Box 87103
: Lincoln, NE 68501-7103
: I-140 Immigration Visa Petition Under First Preference EB-1
| w*********w
发帖数: 959 | 35 Cong!
Thank you OP for sharing. | N****m
发帖数: 236 | 36 cong!!!!! and Thx!!!!!!!!!1
【在 b****n 的大作中提到】
: Address:
: Email:
: Cell phone:
: Work phone:
: Oct 28, 2013
: Department of Homeland Security
: USCIS Nebraska Service Center
: P.O. Box 87103
: Lincoln, NE 68501-7103
: I-140 Immigration Visa Petition Under First Preference EB-1
| c****l
发帖数: 1280 | | p******9
发帖数: 153 | 38 Wuhan University? 恭喜
★ 发自iPhone App: ChineseWeb 7.8
【在 b****n 的大作中提到】
: Address:
: Email:
: Cell phone:
: Work phone:
: Oct 28, 2013
: Department of Homeland Security
: USCIS Nebraska Service Center
: P.O. Box 87103
: Lincoln, NE 68501-7103
: I-140 Immigration Visa Petition Under First Preference EB-1
| p*********r
发帖数: 303 | | w*****c
发帖数: 7276 | | | | n******y
发帖数: 1821 | 41 Cong~
【在 b****n 的大作中提到】
: Address:
: Email:
: Cell phone:
: Work phone:
: Oct 28, 2013
: Department of Homeland Security
: USCIS Nebraska Service Center
: P.O. Box 87103
: Lincoln, NE 68501-7103
: I-140 Immigration Visa Petition Under First Preference EB-1
| z********4
发帖数: 533 | | e***e
发帖数: 286 | | C*******d
发帖数: 3345 | 44 gxgx
zan!
【在 b****n 的大作中提到】
: Address:
: Email:
: Cell phone:
: Work phone:
: Oct 28, 2013
: Department of Homeland Security
: USCIS Nebraska Service Center
: P.O. Box 87103
: Lincoln, NE 68501-7103
: I-140 Immigration Visa Petition Under First Preference EB-1
| a********3
发帖数: 587 | | d****y
发帖数: 250 | | m***o
发帖数: 272 | | f**s
发帖数: 968 | | b****n
发帖数: 8 | 49 Address:
Email:
Cell phone:
Work phone:
Oct 28, 2013
Department of Homeland Security
USCIS Nebraska Service Center
P.O. Box 87103
Lincoln, NE 68501-7103
I-140 Immigration Visa Petition Under First Preference EB-1
Petitioner/Beneficiary: XX Z., Ph.D.
Category of Petition: Alien of Extraordinary Ability
Classification Sought: 203(b)(1)(A)
Nature of Submission: Original Submission
Dear Immigration Officer,
This letter is respectfully submitted in support of my petition for
classification as a qualified immigrant under the first preference as an
Alien of Extraordinary Ability. Specifically, the evidence submitted will
prove:
I. I am an alien of extraordinary ability on the basis of the following
facts:
1. I have authored scholarly articles in professional journals in my field.
2. I have made original scientific contributions of major significance to my
field.
3. I have been asked to judge the work of others.
II. I will continue to work in my area of extraordinary ability in the U.S.
III. My future stay will substantially benefit prospectively the U.S.
I. I am an alien of extraordinary ability on the basis of the following
facts:
I have many years of research experience in biology and biomedicine in very
prestigious institutions, which is summarized in the CV (Exhibit-Edu 1). In
2004, I began my PhD research in Chinese Academy of Sciences (CAS), the top
1 research institute in China and Asia according to Nature Publishing Index
2012 (Exhibit-Edu 2). I received my PhD degree from CAS in 2008 (Exhibit-Edu
3). Immediately after that, I joined Professor D.E.’s lab at University of
XX as a postdoc researcher. UXX has the only school of medicine in the U.S.
that ranks in the top 4 in both research and primary care education
according to US News 2013 (Exhibit-Edu 4). After 5 years’ postdoc research
at UXX, I am now appointed by UXX as an Assistant Professional Research
Biologist (See Employment Verification). With these research experiences, I
have made significant contributions and established my extraordinary ability
in my field.
My contributions have dramatically advanced molecular medicine and genomic
biology, and resulted in 20 scientific papers (Exhibit-Pub 1-20) in
professional journals. On many of these papers, I am the first author or the
key person. These research papers have been cited 562 times (Exhibit-Pub 32
) by researchers around the world, evidencing the worldwide impact. Owing to
my expertise, I have been invited to judge the work of others 18 times (
Exhibit-Rev 1-18) for leading journals and have been considered as one of
the best reviewers (Exhibit-RL 5). Through these publications and original
contributions, I have achieved sustained national and international acclaim
and reputation in my field on a much higher scale than the vast majority of
others in my research area. Consistent with these facts, leading experts in
my field have provided 5 independent advisory evaluations (1 from Ireland, 1
from Germany, 2 from USA, and 1 from Korea, Exhibit-RL 1-5) that have
explained, in detail, how my contributions were “original” and how they
were of “major” significance. The following sections will discuss the
above evidence in further detail.
1. My Authorship of Scholarly Articles in professional Journals in My Field
I have published 20 scientific articles in professional journals with
worldwide circulation. The full copies of my publications are packed as
Exhibit-Pub 1-20. The brief summary for the journals where I have published
my articles is shown in Table 1.
Table 1. The summary for the journals that have published my articles
Journal Name IF (2012) IF (5-year) # of My Papers
J Molecular Medicine 4.768 5.012 1
J Biomed Mater Res (A) 2.834 3.103 4
Biomaterials 7.604 8.496 3
PLoS one 3.730 4.244 1
Stem Cells 7.701 8.368 1
Tissue Engineering 4.065 4.623 3
Neuroscience Letters 2.026 2.146 3
Growth Factors 2.195 2.337 1
Proc Am Thor Soc New journal, IF not available now 1
Acta Hydrobiologica Sinica In Chinese, with English abstract 1
Wuhan University J Nat Sci In Chinese, with English abstract 1
TOTAL 20
Impact Factor (IF), which is published by Thomson Reuters on the basis of
the citation rates of papers, is widely used to evaluate the impact of
journals. Generally, the higher IF score means higher impact. In addition,
the reputation is also a criterion for evaluating a journal. Here I am
briefly describing the reputation and IFs for these journals:
o Journal of Molecular Medicine (JMM) publishes reports describing major
advances in the understanding, prevention, diagnosis, and treatment of human
disease through the application of molecular biology and gene technology.
JMM is the continuation of the Berliner Klinische Wochenschrift (1864), one
of the oldest and most prestigious European journals in which great
scientists such as Paul Ehrlich (Nobel prize, 1908), Robert Koch (Nobel
prize, 1905) and Otto Warburg (Nobel prize, 1931) published their seminal,
epoch-making discoveries. JMM’s IF is ranked # 18 /121 in medicine,
research & experimental (Exhibit-Pub 21).
o Journal of Biomedical Materials Research Part A is the official journal
of the Society For Biomaterials (USA), the Japanese Society for
Biomaterials, the Australasian Society for Biomaterials, and the Korean
Society for Biomaterials, ranked #8 among all journals in materials science
& biomaterials (Exhibit-Pub 22).
o Biomaterials is an international journal covering the science and
clinical application of biomaterials. It publishes original papers and
authoritative review and opinion papers dealing with the most important
issues facing the use of biomaterials in clinical practice. Biomaterials is
ranked #1 among all journals in materials science & biomaterials (Exhibit-
Pub 23).
o PLoS One is a peer-reviewed journal dedicated to publishing high
quality research. Submissions are considered on the basis of scientific
validity and technical quality (Exhibit-Pub 24).
o Stem Cells covers all aspects of stem cells embryonic stem cells/
induced pluripotent stem cells; tissue-specific stem cells; stem cell
technology: epigenetics, genomics, proteomics, and metabonomics; cancer stem
cells; translational and clinical research; and regenerative medicine. Stem
cells is ranked #2 among all journals in cell & tissue engineering (Exhibit
-Pub 25).
o Tissue Engineering is the preeminent, biomedical journal advancing the
field with cutting-edge research and applications on all aspects of tissue
growth and regeneration, ranked # 8 among all journals in cell & tissue
engineering (Exhibit-Pub 26).
o Neuroscience Letters is devoted to the rapid publication of short, high
-quality papers. Only papers that will make a significant addition to the
literature in the field will be published (Exhibit-Pub 27).
o Growth Factors is an international and interdisciplinary vehicle
publishing new knowledge and findings on the regulators of cell
proliferation, differentiation and survival (Exhibit-Pub 28).
o Proc Am Thor Soc is an official international journal of the American
Thoracic Society, the Annals of the American Thoracic Society (Annals ATS),
formerly the Proceedings of the American Thoracic Society (PATS). It
delivers up-to-date and authoritative coverage of adult and pediatric
pulmonary and respiratory sleep medicine and adult medical critical care.
The scope of the journal encompasses content that is applicable to clinical
practice, and the clinical advancement of public health (Exhibit-Pub 29).
o Acta Hydrobiologica Sinica (AHS) is launched in 1955 and sponsored by
the Institute of Hydrobiology, Chinese Academy of Sciences, and the Chinese
Society for Oceanology and Limnology. AHS is a comprehensive academic
journal dedicated to the timely publication of original research ideas and
results in all fields of hydrobiology (Exhibit-Pub 30).
o Wuhan University Journal of Natural Sciences aims to promote rapid
communication and exchange between the world and Wuhan University, as well
as other Chinese universities and academic institutions. It mainly reflects
the latest advances being made in many disciplines of scientific research in
Chinese universities and academic institutions (Exhibit-Pub 31).
Besides the journal impact factor and reputation, the quality of a paper can
be reflected by the citations in other people’s work. Several tools with
different strengths are available for the evaluation of citations. For
example, Google Scholar Citations has the most powerful search engine so
that it can find the biggest number of citations; however, it is easier to
show the citation distribution in countries through Web of Knowledge (
Thomson Reuters). So I will next use these tools, depending on different
purposes, to show you the citations of my papers.
Figure 1 shows the total citations (left) and annual citations (right) of my
papers according to Google Scholar Citations. It shows that my papers have
been cited over 560 times in total and the annual citations are rising (More
information can be found in Exhibit-Pub 32), indicating that my papers have
been widely recognized.
Figure 1. The total and annual citations of my papers *
(* The total citation from another tool Scopus is attached immediately after
Exhibit-Pub 32, with the exhibit name SNEP-32)
To be emphasized, the average citation rate of my papers is >28 (562/20),
which is significantly higher than the average citation rates in clinical
medicine (12.84) and materials science (7.76) (Exhibit-Pub 35), indicating
that my publication is superior to my peers.
Owing to the novelty and importance of my work, the authors from many
countries have cited my papers. The Web of Knowledge displayed the countries
where the researcher have cited my papers, which include China, USA, Korea,
Germany, Italy, Japan, England, Switzerland (see the top 20 in Figure 2,
detailed in Exhibit-Pub 33), suggesting that my papers have been
internationally recognized.
Figure 2. Top 20 countries where researchers have cited my papers
Furthermore, my papers have been cited by many of very prestigious journals.
The analysis with Google Scholar Citations shows you all the articles and
journals that have cited my papers (Exhibit-Pub 32), while Table 2 shows you
, in detail, 10 examples of prestigious journals that have cited my papers.
Details about the 10 citing papers, the relevant journal names and their
impact factors are shown in Exhibit-Pub 34. They are also positioned in
Exhibit-Pub 32 with red flags.
Table 2. 10 examples of prestigious journals citing my papers
Journal name IF 2012 IF 5-year
Nature Reviews Genetics 41.063 36.4
Nature Immunology 26.199 25.005
Nature Reviews Neuroscience 31.673 35.888
Biomaterials 7.604 8.496
Molecular and Cellular Biology 5.372 5.745
Stem Cells 7.701 8.368
Biotechnology Advances 9.599 11.85
Cell Research 10.526 10.216
Molecular Therapy 7.041 6.457
P.N.A.S 9.737 10.583
In summary, I have published 20 scientific papers in professional journals.
Some journals are # 1 in the field and some are very top and prestigious
journals. These papers have been cited 562 times by other researchers over
20 countries, demonstrating the worldwide impact. The average citation of my
papers is much higher than the average citation rate in the field.
Therefore, my publication record is extraordinary and my works constitute
authorship of scholarly articles in professional journals that have
significantly influenced my field.
2. My Original Scientific Contributions of Major Significance to My field
Although the significance of my scientific contributions can be generally
reflected by 20 articles that have been cited over 20 countries for 562
times, more details about my work will further clarify that. Specifically, I
have made multiple, original, recognized contributions to the field of
molecular medicine and molecular biology. The aim of molecular medicine is
to treat diseases by developing of molecular approaches such as gene
engineering and recombinant proteins. These approaches, combined with cells,
biomaterials, and engineering, can be further applied to tissue engineering
for repairing or replacing damaged tissues such as blood vessels, bone,
cartilage, skin, muscle etc. Molecular medicine is at the forefront of
modern medicine and is becoming increasingly important, because many
problems with patients cannot be solved with traditional treatments. For
example cardiovascular diseases (CVDs) are the number one cause of death
globally: An estimated 17.3 million people died from CVDs in 2008,
representing 30% of all global deaths. The number will increase to reach 23.
3 million by 2030 (World Health Organization’s report: http://www.who.int/mediacentre/factsheets/fs317/en/). An essential step to cure of CVDs is to regenerate blood vessels or promote neovascularization. However, it is very challenging to regenerate blood vessels in many of damaged tissues or organs. Although some treatments are available clinically, they mostly are of low efficacy or they rely on autografts or allografts but have associated risks, with autografts needing an additional surgical site and limits to supply, and allografts having potential risks of disease transmission and long-term complications. To solve these challenging obstacles, I have made significant contributions to regeneration of blood vessels and therapeutic neovascularization by development of molecular medicine approaches, which include the recombination of fibrin-affinity fusion growth factor, invention of 3-D biomaterial scaffolds, reconstruction of targeted repair system based on fibrin and collagen. These cutting-edge technologies have been proved to be very efficacious in neovascularization and improvement of wound healing. My contributions in this area have shown considerable value in clinical applications and brought great hope for millions of patients with CVDs (Exhibit-RL 1-5).
In one of my work, I developed a novel molecular technology for targeted
improvement of neovascularization. It has been proved that bFGF can set the
stage for neovascularization during embryonic development. Therefore, bFGF
is supposed to be a reagent for therapeutic neovascularization. However,
previous work with the local application of bFGF to wound sites resulted in
subtle effects, because bFGF diffused rapidly via conventional
administration ways, thus markedly lowered its effects. To solve this
clinical obstacle, I developed a molecular technology for targeted
application of bFGF. Targeted therapy is a new generation of therapeutics,
by which the drug acts only on specific targets and avoids adverse effects
on other tissues. First, a fibrin binding peptide Kringle 1 (K1) was fused
to bFGF, which successfully endowed bFGF with fibrin binding ability. Second
, the recombinant K1bFGF was incorporated with fibrin. In vitro assay with
fibrin showed that K1bFGF was released in a sustained and controlled manner,
rather than the burst release with natural bFGF. After application to the
wound sites in animals, fibrin/K1bFGF markedly induced vascular endothelia
cells proliferation and new blood vessel formation at wound sites. Six weeks
after treatment, the wound sites treated with fibrin/K1bFGF were repaired
completely, but the control samples did not lead to significant repair.
These results demonstrated a very promising technology that could be used
for clinical therapy of CVDs and wound healing. The further application of
this technology in tissue engineering will be of great value.
This work has been published in Journal of Molecular Medicine with my name
as the first author (Exhibit-Pub 1) and highly acclaimed by independent
experts: “The complex of fibrin with K1゜FGF strikingly regenerated the
blood vessel network and improved wound repair, demonstrating a powerful
tissue〆ngineered product.” (Prof. BB, Exhibit-RL 1); “Dr. XX Z. was the
first person that creatively developed the Fibrin/K1-bFGF system and
successfully established an efficacious method for targeted improvement of
neovascularization. This work showed a very promising perspective for the
therapy of ischemic diseases clinically.” (Prof. AA, Exhibit-RL 2). This
work is also highlighted in experts’ review papers. For example, in Prof.
BB’s (an independent advisory expert) paper, it says “A recent approach to
tether growth factors has been investigated by Z. et al. Kringle domains
present on the enzymogen plasminogen have high affinity for fibrin...
Analysis of binding showed that K1bFGF bound fibrin with a greater affinity
than bFGF alone, and was also retained for longer in a fibrin scaffold than
bFGF… results showed that fibrin containing K1bFGF significantly enhanced
neovascularization… it was shown that fibrin scaffolds containing K1bFGF
had significantly more proliferating cells than control groups, highlighting
the importance of prolonging the diffusion of growth factors in vivo.” (
Tissue Engineering: Part B, 2009, Ref. 117, Exhibit-Con1).
Moreover, this work attracted editor’s special attention. Dr. AA, an editor
of the Journal of molecular medicine, “thought that this paper was the
best paper in that issue, so he wrote a three-page commentary on this work”
in that issue (Exhibit-RL 2): “In this issue, Z. et al. demonstrate
improved neovascularization and wound repair by targeting human bFGF to
fibrin… This system successfully induced neovascularization by delivering
K1-bFGF in a sustained fashion. The result was a microenvironment that
promoted cell growth, angiogenesis, and tissue regeneration… This strategy
could potentially be used in other clinical settings because plasminogen and
angiostatin can promote blood vessel formation in ischemic cardiovascular
disease and turn the process off in cancer, respectively. Z. et al. have
picked the targets and vehicles to potentially do both”(detailed in Exhibit
-Con2). Therefore, this work demonstrates a significant contribution to
therapeutic neovascularization.
Scaffolds with 3-D structure can mimic the in vivo environment and promote
tissue regeneration. To achieve this goal, I developed a 3-D scaffold based
on fibrin protein for blood vessel regeneration. Scanning electron
microscopy revealed that the microscopic structure of the 3-D scaffold was
honeycomb-like, with an average pore size of 50 µm, demonstrating a
similar 3-D structure to that of natural fibrin clots. Therefore, the
polyporous 3-D structure is suitable for cell migration and growth. Further,
fibrin fibers were cross-linked and well organized, and provided potential
binding sites for signal molecules participating in tissue regeneration. To
target bFGF to the 3-D fibrin scaffold, I fused Kringle 4 (K4) peptide to
bFGF and resulted in a fusion molecule K4bFGF. Kringle 4 is a shortened
analog to Kringle 1 but has a lower molecular weight, thus increased yield
when expressed in bacteria. In vitro assays showed that 3-D fibrin scaffold
could bind specifically to K4bFGF and deliver K4bFGF in a site-specific
manner. Cell culture assay showed the 3-D fibrin scaffold significantly
promoted cell migration and proliferation. Subcutaneous implantation of 3-D
fibrin scaffolds bound with K4bFGF, but not with natural bFGF, induced
significant formation of new blood vessels in animals. Moreover, the
regenerative tissues were integrated well with the fibrin scaffolds,
suggesting its excellent biocompatibility and therapeutic prospect.
This work has been published in Tissue Engineering (Part A) with my name as
the first author (Exhibit-Pub 2) and demonstrated a significant advancement
in regeneration of blood vessels. Due to its great value in clinical
application, this work has been highlighted in Dr. Koutsopoulos’ (
Massachusetts Institute of Technology, Exhibit-Con 3) review paper: “Z. et
al. studied the release of growth factors through a modified fibrin
nanofiber hydrogel in which basic fibroblast growth factor (bFGF) was
tethered to fibrin nanofibers via the kringle domains that are present on
plasminogen. In vivo studies showed that fusion of the Kringle domain (K4)
to the N-terminus of bFGF and binding to the fibrin nanofibers resulted in
longer retention and prolonged release of the tethered bFGF compared to the
native bFGF encapsulated in the fibrin hydrogel” (Advanced Drug Delivery
Reviews, IF 12.888, 2012, Ref 75, Exhibit-Con 3/4). Moreover, this work has
been highly acclaimed by independent experts: “The modified fibrin scaffold
obtained great mechanical strength after vacuum lyophilization…Millions of
people in the world need therapeutic neovascularization due to pathological
ischemia or accidental injures. This impressive work showed a very
promising avenue to the therapeutic neovascularization in patients, and
represents a significant contribution to regenerative medicine.” (Prof. DD,
Exhibit-RL 4); “More expressively, he next developed a 3-D fibrin scaffold
to enable cells grow in 3-D environment rather than in 2-D space, which
allowed cells to interact with each other. By incorporating the hybrid K4-
bFGF into the 3-D fibrin scaffold, his results showed that the repair system
markedly improved new blood vessel growth and wound healing. His work has
greatly advanced the therapeutic regeneration of blood vessels.” (Prof. EE,
Exhibit-RL 5).
In the next work, I developed another type of targeted-therapy technology on
the basis of collagen for neovascularization. Collagen is a type of
biomaterial that is widely used in tissue engineering but the natural
collagen molecules cannot be incorporated with bFGF. I recombined bFGF into
a fusion protein by introduction of collagen binding domains (CBDs) via gene
engineering technology. The resulting CBD-bFGF could bind specifically to
collagen that has been fabricated into a 3-D scaffold. By incorporation of
CBD-bFGF to collagen scaffold, the diffusion problem with bFGF was
successfully solved. Moreover, the collagen scaffold could provide 3-D space
supporting cell migration and growth. Upon implantation, this system
markedly promoted neovascularization and endothelial cell growth.
This work has been published in Journal of Biomedical Materials Research (
Part A) with my name as the first author (Exhibit-Pub 3) and shown a
significant improvement of neovascularization via use of molecular medicine
approach. This work was highlighted in Dr. CHONG-SU CHO’s review article (
Seoul National University, ranked #1 in Korea, Exhibit-Con5): “Z. et al
introduced two CBDs into the human bFGF to develop a collagen based wound
targeting repair system. The results showed that the bFGF with the CBD
derived from collagenase (C-bFGF) promoted vascularization at the implanted
sites more effectively than bFGF…”(Annals of Biomedical Engineering, 2010,
Ref. 87, Exhibit-Con6). Due to my successful application of CBDs in
collagen-based targeted technology, Dr. Eiry Kobatake’s group (Tokyo
Institute of Technology, ranked #4 in Japan, Exhibit-Con 7) used this work
as a basis to design the new multi-functional extracellular matrix proteins
that promote tube formation of endothelial cells. Please see the details on
page 2978 of Exhibit-Con 8: “Here, we focused on the collagen-binding
domain (CBD)…[28-30]. Thus, we constructed new fusion proteins in order to
obtain the multiple activities” (Biomaterials, 2008, Ref. 29, Exhibit-Con 8
). Moreover, this work are highly recognized by independent experts and
shown the potential for the application in tissue engineering: “this
product strikingly promoted vascular endothelial cell growth and wound
healing in rat preclinical studies. This work demonstrated an innovative
tissue engineering product that could be clinically translated.” (Prof. BB,
Exhibit-RL 1); “he successfully developed the collagen/ growth-factor
system… for the purpose of therapy of ischemia… These extensive
contributions significantly promoted the research in biomedicine.”(Prof. AA
, Exhibit-RL 2). Therefore, my work has been recognized to be significant to
the field. These contributions to the therapeutic neovascularization with
targeted technologies could potentially benefit millions of patients who are
suffering from ischemic diseases including CVDs.
The facts above just show some representatives of my contributions to the
field of molecular medicine; all of my other contributions to molecular
medicine and related fields are reflected by the full list of papers. My
most recent work is focused on genome biology, which is one of the hottest
areas in molecular biology. Genomics is changing the way people think about
life sciences, and it will benefit the entire medicine including molecular
medicine and genomic medicine. A fundamental step towards the genomic
medicine is to decode the genetic information within 3 billion of human DNA
bases. However, most of the DNA sequences are not functionally annotated due
to the lack of high throughput technologies. I have therefore developed a
massively parallel technology (named fast-UTR) to systematically unveil the
regulatory functions of 3’ untranslated region (3’UTR) sequences. 3’UTR
is a partial sequence of mRNA and plays critical roles in controlling of
gene expression. The human genome contains thousands of 3’UTR sequences,
but only very few of them have been investigated with low throughput methods
. By using fast-UTR, I, as a “key role” (See Employment Verification),
have revealed the regulatory effects of 450kb conserved 3’UTR sequences on
mRNA abundance, mRNA decay rate and translation. I further systematically
identified the functional cis-elements within these sequences. This exciting
work for the first time demonstrated a powerful technology that can be used
to functionally unveil DNA or RNA sequences in genome wide.
One paper about this work has been published in Proc Am Thor Soc with my
name as the first author (Exhibit-Pub 5), which is the only paper so far
that has been published for systematic understanding of 3’ untranslated
regions (Exhibit-Con9), demonstrating a pioneering work in this area. More
excitingly, a recent manuscript about this project has been submitted to
Nature Biotechnology (IF 32.438) with my name as the first author and is now
under review (Exhibit-Con 10). Another manuscript is ready to submit (
Exhibit-Con 11). These facts demonstrate that I am continuously making
significant contributions. Due to the novelty and importance, this work is
highly praised by experts. Prof. N. CC, an expert in genome biology in Yale
University, gives an independent evaluation: “The fast-UTR is a highly
integrative tool encompassing aspects of molecular biology, cellular biology
, genome biology, and computational biology… This clever system has been
shown to be very efficient in systematic quantification of the regulatory
effects of 3’UTRs on proteins. The results also elucidated the
relationship between the mRNA level and protein level controlled by 3’UTRs.
Undoubtedly, this original work is a significant innovation in this field…
This technology and the findings could be potentially useful in genomic
medicine in future” (Exhibit-RL 3). “The discoveries in this work have
deepened the understanding of the functions of evolutionarily conserved 3’
UTRs; this novel technology will dramatically advance the genome research”,
independently evaluated by Prof. DD (Exhibit-RL 4). Therefore, these recent
accomplishments and ongoing progress prove my sustained extraordinary
ability to do high quality of research.
In Summary, my work has been shown with great values in both clinical
application and basic research; my work has been widely cited in the world
by many of prestigious scientific journals and famous institutions; my work
has been totally cited for 562 times over 20 countries as supporting data or
used a the basis in other research. The comparison of my publication and
citations to the average of faculty scholarly productivity in TOP research
universities indicates my superiority to peers. Table 3 shows the average
publication and citations in top 10 universities in biological and
biomedical sciences, which clearly shows that my “publication”, total “
citations” and “citations per paper” are all much higher than the average
level with the faculty in top universities, indicating that I am far
superior to my peers.
Table 3. Comparison of my publication and citations to the average levels
with the faculty in TOP 10 universities (The full table is shown in Exhibit-
Con 12)
Institution Publications per faculty Citations per faculty
Citations per paper
1 U. of California at San Diego 16 327 16
2 Gerstner Sloan-Kettering Graduate School of Biomedical Sciences 14
324 18
3 U. of California at San Francisco 10 234 17
4 Vanderbilt U. 10 138 11
5 U. of North Carolina at Chapel Hill 9 161 14
6 U. of Massachusetts Medical School 8 169 17
7 Mount Sinai School of Medicine 10 128 10
8 U. of Colorado at Denver and Health Sciences Center 7 110 12
9 U. of Cincinnati 10 137 10
10 New York U. 8 134 13
Average 10 186 14
My Publication and Citations 20 > 560 > 28
Moreover, my work has been highly acclaimed by five independent advisory
experts (1 from Ireland, 1 from Germany, 2 from USA, and 1 from Korea,
Exhibit-RL 1-5), and they have testified the “originality” and “major
significance” of my contributions. All these facts therefore prove that I
have made multiple original contributions of major significance to my field.
3. My Service As a Judge of the Work of Others
Owing to my outstanding expertise and excellent reputation in my field, I
have been invited to judge the work of others for 18 times by professional
journals, which are shown in the list below. Notably, all these invitations
were made under my name (Exhibit-Rev 1-18).
o Journal of Materials Chemistry B
o Soft Matter
o Biomaterials Science
o International Journal of Nanomedicine
o Medical & Biological Engineering & Computing
o Australasian Physical & Engineering Sciences in Medicine
o Science China-Chemistry
All of these journals are professional publications (Exhibit-Rev 19-25). For
example, Journal of Materials Chemistry B (JMC-B), a very prestigious
journal, is an official publication of Royal Society of Chemistry and has an
impact factor 6.10. The journal is interdisciplinary, publishing work of
international significance on all aspects of materials chemistry related to
biology and medicine. It publishes original research that demonstrates
novelty and advance (Exhibit-Rev 19). Softer Matter has an impact factor 3.
909 and is ranked #8/83 (Exhibit-Rev 20); Biomaterials Science, opened in
2012, is an international, high impact journal (Exhibit-Rev 21).
International Journal of Nanomedicine (IJN), endorsed by the American
Society for Nanomedicine, is an international, peer-reviewed journal, with
an impact factor 3.463 (Exhibit-Rev 22).
“To ensure the quality of outgoing articles, we only recruit researchers
with outstanding credentials as manuscript reviewers. Dr. Z.’s good
reputation makes him an ideal reviewer for IJN… Dr. Z.’s research
expertise and credentials match our high criteria and I consider him as one
of the best reviewers.” (Prof. EE, an editor of IJN, Exhibit-RL 5 and
Exhibit-Rev 22). Owing to my outstanding expertise and good reputation, I
was “recognized as an expert in the field” (Exhibit-Rev 1, 2, 3) and was
invited to review the manuscripts for these professional journals. To screen
papers of high quality, I always seriously evaluate the work of others for
novelty, accuracy, and importance to the field. My service as a reviewer not
only contributes to my field, but also demonstrates my extraordinary
expertise and international acclaim.
The Summary for the Significance of the Evidences:
• I have been doing research in very prestigious institutions
including Chinese Academy of Sciences and University of XX; I am now
appointed as an Assistant Professional Research Biologist at UXX and
continuously doing high quality of research.
• I have published 20 peer-reviewed scientific papers; the papers
have been cited over 560 times by the researchers from over 20 countries.
• I have made original scientific contributions of major
significance to my field. I have been widely recognized by international
experts and have sustained national or international acclaim: “Dr. XX Z.’s
creative work undoubtedly demonstrated his extraordinary ability in
research” (Prof. AA, Exhibit-RL 2); “Dr. XX Z. has made outstanding
accomplishments… Based on his impressive publication record and reputation,
I consider him as one of the top scientists in the field.” (Prof. DD,
Exhibit-RL 4); “Dr. Z. has authored many peer-reviewed papers, which have
been cited over 500 times, demonstrating that he has been internationally
recognized and shown himself to be of extraordinary ability” (Prof. CC,
Exhibit-RL 3).
• I have independently judged the work of others for 18 times for
the professional scientific journals. I have been considered as an ideal and
one of the best reviewers.
• The totality of these evidences demonstrates that I am one of
that small percentage who have risen to the very top of the field of
endeavor, and that I have sustained national or international acclaim and
that my achievements have been recognized in the field of expertise.
Therefore, I am an alien of extraordinary ability.
II. I will continue to work in my area of extraordinary ability in the U.S.
I am very interested in biology and biomedicine; I have demonstrated my
extraordinary ability in these aspects. “Owing to his outstanding
accomplishments and expertise, he has been employed here as an Assistant
Professional Research Biologist since July 28, 2013. He will continue to
play a key role in our studies of the roles of 3’UTRs in
posttranscriptional gene regulation using the fast-UTR system and other
relevant tools and in our studies of micro-RNAs in airway epithelial cells”
(See Employment Verification). Specifically, I will systemically
investigate the post-transcriptional effects of human 3’UTR sequences on
gene expression and identify the functional cis-elements contained in active
3’UTRs in the human genome. Then I will screen the trans-acting factors in
airway epithelial cells that interact with these cis-elements and elucidate
their roles in gene expression. With these systematic studies, I expect to
discover novel regulatory cis-elements and relevant trans-acting factors
including miRNAs and binding proteins. Therefore, I will definitely continue
to work in my area of extraordinary ability in the United States.
III. My future stay will substantially benefit prospectively the U.S.
My future work will lead to understanding of the functions of 3’UTR
sequences and microRNAs in human genome. The research in genome biology will
extensively benefit the whole country and the world. For example, between
1988 and 2010, human genome sequencing projects and associated research and
industry activity, directly and indirectly, generated economic activity
totaling $796 billion, personal income exceeding $244 billion, and 3.8
million job-years of employment. The government’s initial investment
yielded an economic return of 141 to 1. In 2010 alone, genomics-related
economic activity yielded over $3.7 billion in federal taxes and $2.3
billion in state and local taxes. (More information can be found in NIH
official report: http://officeofbudget.od.nih.gov/pdfs/FY13/FY2013_Overview.pdf). More importantly, the findings in genomic studies could be applied in genomic medicine. Genomic medicine is the next generation of medicine that can be used in the therapy of cancer, HIV infection, and heart disease etc., so it will remarkably benefit public health in the U.S.. Owing to my demonstrated extraordinary ability, my future stay will substantially benefit prospectively the United States. “Therefore, it is definitely in the U.S. national interest for Dr. Z. to remain in the U.S. and to continue his research”(Prof. CC, Exhibit-RL 3); “His continued presence in the United States will certainly be highly beneficial to the United States”(Prof. BB, Exhibit-RL 1).
I sincerely hope that I have provided you with the information and
documentation necessary and sufficient to approve my I-140 petition. I
deeply appreciate your kind consideration and care of this application!
Respectfully yours,
XX Z., PhD
Assistant Professional Research Biologist
Department of Medicine
University of XX
INDEX OF EXHIBITS
Education and Research:
Exhibit-Edu 1 My Curriculum Vitae
Exhibit-Edu 2 Ranking of Chinese Academy of Sciences
Exhibit-Edu 3 Copy of My PhD Certificate and Equivalency Evaluation
Exhibit-Edu 4 Ranking of University of XX
Employment Verification:
Verification of Employment for My Postdoc Research and Current Employment
Publication:
Exhibit-Pub 1-20 20 of My Peer-reviewed Publications
Exhibit-Pub 21-31 Description, Impact Factor and Ranking of 11 Journals
in
which I have published papers
Exhibit-Pub 32 Paper Citation Report based on Google Scholar and
Scopus
Exhibit-Pub 33 Paper Citation Report based on Web of Knowledge
Exhibit-Pub 34 10 Examples of Papers Citing My Work
Exhibit-Pub 35 Average Citation Rates for Paper by Field (2002-
2012)
Recommendation Letters From Five Independent Experts:
Exhibit-RL 1 Professor A. BB’s Letter (Ireland)
Exhibit-RL 2 Professor F. AA’s Letter (Germany)
Exhibit-RL 3 Professor N. CC’s Letter (USA)
Exhibit-RL 4 Professor L. DD’s Letter (USA)
Exhibit-RL 5 Professor D. EE’s Letter (Korea)
Contributions:
Exhibit-Con 1 Dr A. BB’s Paper Citing My Work
Exhibit-Con 2 Dr F. AA’s Editorial Commentary on My Work
Exhibit-Con 3 Dr. Koutsopoulos’ Paper Citing My Work
Exhibit-Con 4 Impact Factor and Ranking of Advanced Drug Delivery
Reviews
Exhibit-Con 5 Ranking of Seoul National University
Exhibit-Con 6 Dr CHONG-SU CHO’s paper Citing My Work
Exhibit-Con 7 Ranking of Tokyo Institute of Technology
Exhibit-Con 8 Dr Eiry Kobatake’s Paper Citing My Work
Exhibit-Con 9 Search Results for Work related to My Current Research in
Google
Exhibit-Con 10 My Manuscript Submitted to Nature Biotechnology
Exhibit-Con 11 My Ready-to-submit Manuscript
Exhibit-Con 12 Top Research Universities Faculty Scholarly Productivity
Index
Reviewing the Work of Others:
Exhibit-Rev 1-18 Evidence for My Reviewing of the Work of Others
Exhibit-Rev 19-25 Scientific Journals Relevant to My Reviewing Work | N*******d
发帖数: 1316 | | | | a******t
发帖数: 319 | | s*s
发帖数: 535 | | y********l
发帖数: 794 | | s********s
发帖数: 3945 | 54 恭喜恭喜！多谢分享。
【在 b****n 的大作中提到】
: Address:
: Email:
: Cell phone:
: Work phone:
: Oct 28, 2013
: Department of Homeland Security
: USCIS Nebraska Service Center
: P.O. Box 87103
: Lincoln, NE 68501-7103
: I-140 Immigration Visa Petition Under First Preference EB-1
| l*******7
发帖数: 627 | 55 cong~
【在 b****n 的大作中提到】
: Address:
: Email:
: Cell phone:
: Work phone:
: Oct 28, 2013
: Department of Homeland Security
: USCIS Nebraska Service Center
: P.O. Box 87103
: Lincoln, NE 68501-7103
: I-140 Immigration Visa Petition Under First Preference EB-1
| h*******n
发帖数: 1328 | 56 恭喜恭喜
【在 b****n 的大作中提到】
: Address:
: Email:
: Cell phone:
: Work phone:
: Oct 28, 2013
: Department of Homeland Security
: USCIS Nebraska Service Center
: P.O. Box 87103
: Lincoln, NE 68501-7103
: I-140 Immigration Visa Petition Under First Preference EB-1
| G**S
发帖数: 1108 | | s***s
发帖数: 2360 | | b*l
发帖数: 1118 | | R*******d
发帖数: 13640 | | | | W*******n
发帖数: 2762 | | w****n
发帖数: 175 | 62 zang~~
【在 b****n 的大作中提到】
: Address:
: Email:
: Cell phone:
: Work phone:
: Oct 28, 2013
: Department of Homeland Security
: USCIS Nebraska Service Center
: P.O. Box 87103
: Lincoln, NE 68501-7103
: I-140 Immigration Visa Petition Under First Preference EB-1
| c*******a
发帖数: 1541 | 63 Marked
★ 发自iPhone App: ChineseWeb 8.1
【在 b****n 的大作中提到】
: Address:
: Email:
: Cell phone:
: Work phone:
: Oct 28, 2013
: Department of Homeland Security
: USCIS Nebraska Service Center
: P.O. Box 87103
: Lincoln, NE 68501-7103
: I-140 Immigration Visa Petition Under First Preference EB-1
| s******t
发帖数: 913 | 64 Big big big cong!
【在 b****n 的大作中提到】
: Address:
: Email:
: Cell phone:
: Work phone:
: Oct 28, 2013
: Department of Homeland Security
: USCIS Nebraska Service Center
: P.O. Box 87103
: Lincoln, NE 68501-7103
: I-140 Immigration Visa Petition Under First Preference EB-1
| s*********x
发帖数: 1923 | | v*****e
发帖数: 309 | | H******6
发帖数: 77 | | u****r
发帖数: 2053 | | d***y
发帖数: 8107 | | h*****a
发帖数: 389 | | | | w****2
发帖数: 5760 | | D******K
发帖数: 557 | | b*********f
发帖数: 2125 | 73 10yuede ...恭喜了！
沾点喜气！！！ | C********1
发帖数: 160 | 74 Thanks so much for sharing!
【在 b****n 的大作中提到】
: Address:
: Email:
: Cell phone:
: Work phone:
: Oct 28, 2013
: Department of Homeland Security
: USCIS Nebraska Service Center
: P.O. Box 87103
: Lincoln, NE 68501-7103
: I-140 Immigration Visa Petition Under First Preference EB-1
| h*******e
发帖数: 142 | | s*******c
发帖数: 1366 | | k*f
发帖数: 58 | | p****a
发帖数: 631 | 78 好人，沾喜
【在 b****n 的大作中提到】
: Address:
: Email:
: Cell phone:
: Work phone:
: Oct 28, 2013
: Department of Homeland Security
: USCIS Nebraska Service Center
: P.O. Box 87103
: Lincoln, NE 68501-7103
: I-140 Immigration Visa Petition Under First Preference EB-1
| A******d
发帖数: 571 | 79 牛！恭喜～！
assistant professional research biologist是个什么title,从来没听说过？
你是从哪里找的faculty average citation/publication的？
【在 b****n 的大作中提到】
: Address:
: Email:
: Cell phone:
: Work phone:
: Oct 28, 2013
: Department of Homeland Security
: USCIS Nebraska Service Center
: P.O. Box 87103
: Lincoln, NE 68501-7103
: I-140 Immigration Visa Petition Under First Preference EB-1
| l***d
发帖数: 846 | | | | A******d
发帖数: 571 | 81 再问个问题，那个Faculty Scholarly Productivity Index是指2007年一年的数据吧，
那你的20篇文章是多年积累起来的吧？这样能比吗？
还有我觉得我特别苦逼，我这个领域冷门的都找不到，最多只能算在biology里面，然
后biology的平均引用都很高的，衬托的我的引用更加低。这种该怎么办？
【在 b****n 的大作中提到】
: Address:
: Email:
: Cell phone:
: Work phone:
: Oct 28, 2013
: Department of Homeland Security
: USCIS Nebraska Service Center
: P.O. Box 87103
: Lincoln, NE 68501-7103
: I-140 Immigration Visa Petition Under First Preference EB-1
| c**********n
发帖数: 1982 | 82 gxgx
【在 b****n 的大作中提到】
: Address:
: Email:
: Cell phone:
: Work phone:
: Oct 28, 2013
: Department of Homeland Security
: USCIS Nebraska Service Center
: P.O. Box 87103
: Lincoln, NE 68501-7103
: I-140 Immigration Visa Petition Under First Preference EB-1
| w*********w
发帖数: 959 | 83 Cong!
Thank you OP for sharing. | N****m
发帖数: 236 | 84 cong!!!!! and Thx!!!!!!!!!1
【在 b****n 的大作中提到】
: Address:
: Email:
: Cell phone:
: Work phone:
: Oct 28, 2013
: Department of Homeland Security
: USCIS Nebraska Service Center
: P.O. Box 87103
: Lincoln, NE 68501-7103
: I-140 Immigration Visa Petition Under First Preference EB-1
| c****l
发帖数: 1280 | | p******9
发帖数: 153 | 86 Wuhan University? 恭喜
★ 发自iPhone App: ChineseWeb 7.8
【在 b****n 的大作中提到】
: Address:
: Email:
: Cell phone:
: Work phone:
: Oct 28, 2013
: Department of Homeland Security
: USCIS Nebraska Service Center
: P.O. Box 87103
: Lincoln, NE 68501-7103
: I-140 Immigration Visa Petition Under First Preference EB-1
| p*********r
发帖数: 303 | | n******y
发帖数: 1821 | 88 Cong~
【在 b****n 的大作中提到】
: Address:
: Email:
: Cell phone:
: Work phone:
: Oct 28, 2013
: Department of Homeland Security
: USCIS Nebraska Service Center
: P.O. Box 87103
: Lincoln, NE 68501-7103
: I-140 Immigration Visa Petition Under First Preference EB-1
| z********4
发帖数: 533 | | e***e
发帖数: 286 | | | | C*******d
发帖数: 3345 | 91 gxgx
zan!
【在 b****n 的大作中提到】
: Address:
: Email:
: Cell phone:
: Work phone:
: Oct 28, 2013
: Department of Homeland Security
: USCIS Nebraska Service Center
: P.O. Box 87103
: Lincoln, NE 68501-7103
: I-140 Immigration Visa Petition Under First Preference EB-1
| a********3
发帖数: 587 | | d****y
发帖数: 250 | | m***o
发帖数: 272 | | f**s
发帖数: 968 | | p********r
发帖数: 3243 | | t*********r
发帖数: 4143 | | X***1
发帖数: 16 | | D*********G
发帖数: 130 | | s******a
发帖数: 884 | | | | c*****z
发帖数: 3090 | | z******n
发帖数: 397 | 102 cong!
【在 b****n 的大作中提到】
: Address:
: Email:
: Cell phone:
: Work phone:
: Oct 28, 2013
: Department of Homeland Security
: USCIS Nebraska Service Center
: P.O. Box 87103
: Lincoln, NE 68501-7103
: I-140 Immigration Visa Petition Under First Preference EB-1
| p********r
发帖数: 3243 | | t*********r
发帖数: 4143 | | X***1
发帖数: 16 | | D*********G
发帖数: 130 | | s******a
发帖数: 884 | | c*****z
发帖数: 3090 | | z******n
发帖数: 397 | 109 cong!
【在 b****n 的大作中提到】
: Address:
: Email:
: Cell phone:
: Work phone:
: Oct 28, 2013
: Department of Homeland Security
: USCIS Nebraska Service Center
: P.O. Box 87103
: Lincoln, NE 68501-7103
: I-140 Immigration Visa Petition Under First Preference EB-1
| J****8
发帖数: 117 | 110 Thanks a lot!
big bless |
|
|
|
|
|
|
|
